Developer docs
API playgroundTry for free, no card

Search company profiles

Nykode

Full company profile

uuid0002ucd

Namestring
Nykode
Legal namestring
Nykode Therapeutics ASA
Websiteurl
vaccibody.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway (with an additional office in Lyngby, Denmark), founded in 2007 and publicly listed on the Oslo Stock Exchange under the ticker NYKD and on OTC Markets as VACBF. The company is built around its proprietary Vaccibody immunotherapy platform, a modular molecule technology designed to induce fast, strong, and long-lasting immune responses with a positive safety profile, and which the company states can be tailored via hyper-targeting for applications in cancer, infectious diseases, and autoimmune conditions.

The company's pipeline is currently concentrated in HPV16-positive oncology. Lead asset VB10.16 is an off-the-shelf therapeutic cancer vaccine being advanced in combination with Roche's atezolizumab for advanced cervical cancer under a strategic collaboration with Roche (expanded June 2023). The second lead candidate, abi-suva, is in the Abili-T Phase II randomized trial for HPV16-positive PD-L1-positive recurrent or metastatic head and neck cancer (first patient dosed May 2026), and reported a 38.5% objective response rate versus 19% for standard of care in interim C-03 trial data, with 100% immune response observed in certain dose cohorts. The company also publicly presented AI-Powered Immunotherapy Design capabilities at BioPharma Drug Discovery Nexus 2026, indicating an emerging AI/design layer on the platform.

Nykode operates a partnership-driven, pre-commercial business model. It is pre-revenue from product sales and historically generated income via licensing and collaboration agreements with major pharmaceutical partners; Q4 2025 revenue was $0 after the cancellation of Genentech and Regeneron agreements (versus $6.8M in Q4 2024). Q4 2025 net loss was $8M and operating expenses were $8.1M (down from $12.9M in Q4 2024), with a $60.3M cash position at year-end 2025 supporting stated runway into 2028. The company has 101-250 employees and engages primarily through enterprise-style co-development partnerships rather than a commercial sales motion.

Short descriptiontext

Nykode Therapeutics is a clinical-stage biopharmaceutical company developing modular Vaccibody immunotherapy vaccines, primarily for HPV16-positive cancers (cervical and head and neck), and monetizing its pipeline through pharmaceutical co-development partnerships with companies such as Roche.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic cancer vaccines, immunotherapy platform, biopharmaceutical development, oncology therapeutics, HPV cancer vaccines
Industry2 codes
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Cancer Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Pre-revenue clinical stage company currently generating minimal to no product revenue. Historically generated $6.8M in Q4 2024 from partnership agreements, but Q4 2025 showed zero revenue due to cancelled Genentech and Regeneron agreements. Future revenue dependent on successful clinical development and potential partnership milestones or product commercialization.

seekingalpha.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Vaccibody
Description

The Nykode Therapeutics platform is built around the Vaccibody molecule, inducing fast, strong and long-lasting immune responses for immunotherapy treatments

nykode.com
Core offering1 text field

Nykode Therapeutics develops immunotherapies based on its proprietary Vaccibody platform, a modular molecule technology designed to induce fast, strong, and long-lasting immune responses. Its lead candidates include VB10.16, an off-the-shelf therapeutic cancer vaccine being co-developed with Roche for advanced cervical cancer, and abi-suva (VB-C-03), an experimental immunotherapy for HPV16-positive head and neck cancer currently in the Abili-T Phase II trial.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 38.5% objective response rate for abi-suva in first-line head and neck cancer vs 19% for standard of care
+1 more record
Product overview1 text field

Nykode Therapeutics is a clinical-stage biotechnology company developing immunotherapies based on its Vaccibody™ platform. The platform is a modular immunotherapy technology designed to induce fast, strong, and long-lasting immune responses. The company's product portfolio includes VB10.16, an off-the-shelf therapeutic cancer vaccine being developed in collaboration with Roche, and abi-suva, an experimental immunotherapy candidate for HPV16-positive cancers undergoing clinical evaluation in the Abili-T Phase II trial and VB-C-03 trial. The Vaccibody platform serves as the core technology underlying these therapeutic candidates, enabling tailored hyper-targeting approaches for oncology and infectious disease applications.

Product and service1 record
1Vaccibody Immunotherapy Platform
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

In June 2023, Norway-based Nykode Therapeutics expanded collaboration with Swiss healthcare company Roche to advance VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche's atezolizumab for patients with advanced cervical cancer. This is a significant strategic partnership for clinical development and potential commercialization.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership agreement that was subsequently cancelled, reducing Q4 2025 revenue to zero from previous levels.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership agreement that was subsequently cancelled, contributing to reduced revenue in Q4 2025.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Achilles Therapeutics develops personalized cancer immunotherapies based on patient-specific tumor neoantigens using T-cell therapies. Comparable to Nykode as a clinical-stage personalized cancer immunotherapy company targeting solid tumors with patient-specific approaches.

TypeDirect peer
Description

Gritstone bio develops personalized neoantigen cancer vaccines (GRANITE, SLATE programs) using viral vectors and self-amplifying RNA. Highly comparable to Nykode in clinical-stage personalized cancer immunotherapy targeting solid tumors.

TypeBroad incumbent
Description

Merck is a global pharmaceutical leader with Keytruda (pembrolizumab) as the dominant PD-1/PD-L1 immunotherapy, often used in combination with therapeutic cancer vaccines including Moderna's mRNA-4157. Comparable as a likely combination partner and acquirer of clinical-stage cancer vaccine assets like Nykode's pipeline.

TypeDirect peer
Description

Nouscom is a clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vector platforms. Closely comparable to Nykode's Vaccibody platform in terms of stage, modality (viral vector-based immunotherapies), and oncology focus.

5Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb is a major immuno-oncology player with Opdivo (nivolumab) and Yervoy (ipilimumab). Comparable as a broad incumbent with overlapping combination immunotherapy interests relevant to Nykode's checkpoint inhibitor combination strategy.

6Hookipa Pharma
TypeEmerging player
Description

Hookipa Pharma develops arenavirus-based immunotherapies for cancer and infectious diseases. Comparable to Nykode as a clinical-stage platform-based immunotherapy company, though using a distinct viral vector technology for antigen delivery.

TypeDirect peer
Description

Immatics develops TCR-based immunotherapies and adoptive cell therapies targeting tumor-specific antigens, including ACTengine and TCER programs. Comparable to Nykode as a clinical-stage European immunotherapy company focused on cancer vaccines and cellular approaches.

TypeDirect peer
Description

Moderna operates an mRNA therapeutics platform with active personalized cancer vaccine programs (e.g., mRNA-4157 with Merck). Comparable to Nykode as a platform-based therapeutic vaccine company targeting oncology, with similar partnership-driven business model.

TypeDirect peer
Description

CureVac develops mRNA-based cancer vaccines and protein-based therapeutics. Comparable to Nykode as a clinical-stage European biotechnology company focused on therapeutic cancer vaccines with a platform-based approach.

TypeDirect peer
Description

BioNTech is a clinical-to-commercial mRNA-based immunotherapies company developing personalized cancer vaccines (e.g., BNT122/Autogene cevumeran) with Roche. Direct comparable to Nykode's Vaccibody platform in therapeutic cancer vaccines, especially in HPV-induced and personalized neoantigen indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nykode

Therapeutic Cancer Vaccinesvaccibody.com

Nykode Therapeutics is a clinical-stage biopharmaceutical company developing modular Vaccibody immunotherapy vaccines, primarily for HPV16-positive cancers (cervical and head and neck), and monetizing its pipeline through pharmaceutical co-development partnerships with companies such as Roche.

What Nykode does

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway (with an additional office in Lyngby, Denmark), founded in 2007 and publicly listed on the Oslo Stock Exchange under the ticker NYKD and on OTC Markets as VACBF. The company is built around its proprietary Vaccibody immunotherapy platform, a modular molecule technology designed to induce fast, strong, and long-lasting immune responses with a positive safety profile, and which the company states can be tailored via hyper-targeting for applications in cancer, infectious diseases, and autoimmune conditions.

The company's pipeline is currently concentrated in HPV16-positive oncology. Lead asset VB10.16 is an off-the-shelf therapeutic cancer vaccine being advanced in combination with Roche's atezolizumab for advanced cervical cancer under a strategic collaboration with Roche (expanded June 2023). The second lead candidate, abi-suva, is in the Abili-T Phase II randomized trial for HPV16-positive PD-L1-positive recurrent or metastatic head and neck cancer (first patient dosed May 2026), and reported a 38.5% objective response rate versus 19% for standard of care in interim C-03 trial data, with 100% immune response observed in certain dose cohorts. The company also publicly presented AI-Powered Immunotherapy Design capabilities at BioPharma Drug Discovery Nexus 2026, indicating an emerging AI/design layer on the platform.

Nykode operates a partnership-driven, pre-commercial business model. It is pre-revenue from product sales and historically generated income via licensing and collaboration agreements with major pharmaceutical partners; Q4 2025 revenue was $0 after the cancellation of Genentech and Regeneron agreements (versus $6.8M in Q4 2024). Q4 2025 net loss was $8M and operating expenses were $8.1M (down from $12.9M in Q4 2024), with a $60.3M cash position at year-end 2025 supporting stated runway into 2028. The company has 101-250 employees and engages primarily through enterprise-style co-development partnerships rather than a commercial sales motion.

Nykode firmographics

Firmographics
Name
Nykode
Legal name
Nykode Therapeutics ASA
Website
https://vaccibody.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
Nykode Therapeutics is a clinical-stage biopharmaceutical company developing modular Vaccibody immunotherapy vaccines, primarily for HPV16-positive cancers (cervical and head and neck), and monetizing its pipeline through pharmaceutical co-development partnerships with companies such as Roche.
Ownership category
akta.pro rank

Where Nykode is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

Nykode business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Partnership and Collaboration Revenue: Pre-revenue clinical stage company currently generating minimal to no product revenue. Historically generated $6.8M in Q4 2024 from partnership agreements, but Q4 2025 showed zero revenue due to cancelled Genentech and Regeneron agreements. Future revenue dependent on successful clinical development and potential partnership milestones or product commercialization.

Go-to-market motion1 record

Marketing channels4 records

Nykode product offering

Product offering

Core offering

Nykode Therapeutics develops immunotherapies based on its proprietary Vaccibody platform, a modular molecule technology designed to induce fast, strong, and long-lasting immune responses. Its lead candidates include VB10.16, an off-the-shelf therapeutic cancer vaccine being co-developed with Roche for advanced cervical cancer, and abi-suva (VB-C-03), an experimental immunotherapy for HPV16-positive head and neck cancer currently in the Abili-T Phase II trial.

Product overview

Nykode Therapeutics is a clinical-stage biotechnology company developing immunotherapies based on its Vaccibody™ platform. The platform is a modular immunotherapy technology designed to induce fast, strong, and long-lasting immune responses. The company's product portfolio includes VB10.16, an off-the-shelf therapeutic cancer vaccine being developed in collaboration with Roche, and abi-suva, an experimental immunotherapy candidate for HPV16-positive cancers undergoing clinical evaluation in the Abili-T Phase II trial and VB-C-03 trial. The Vaccibody platform serves as the core technology underlying these therapeutic candidates, enabling tailored hyper-targeting approaches for oncology and infectious disease applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Vaccibody: The Nykode Therapeutics platform is built around the Vaccibody molecule, inducing fast, strong and long-lasting immune responses for immunotherapy treatments

Products and services

  • Vaccibody Immunotherapy Platform

Quantifiable outcome

  • 38.5% objective response rate for abi-suva in first-line head and neck cancer vs 19% for standard of care
  • +1 more outcomes

Companies that use Nykode

Customer profile

Segments1 record

Ideal customer profiles2 records

Nykode technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nykode partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Roche Holding AGcoreStrategic or Co-development Partner · 1 June 2023In June 2023, Norway-based Nykode Therapeutics expanded collaboration with Swiss healthcare company Roche to advance VB10.16, an off-the-shelf therapeutic cancer vaccine, in combination with Roche's atezolizumab for patients with advanced cervical cancer. This is a significant strategic partnership for clinical development and potential commercialization.
  • GenentechminorStrategic or Co-development PartnerPartnership agreement that was subsequently cancelled, reducing Q4 2025 revenue to zero from previous levels.
  • RegeneronminorStrategic or Co-development PartnerPartnership agreement that was subsequently cancelled, contributing to reduced revenue in Q4 2025.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Nykode competitors and assessment

Company assessment

Direct peers

  • Achilles Therapeutics: Achilles Therapeutics develops personalized cancer immunotherapies based on patient-specific tumor neoantigens using T-cell therapies. Comparable to Nykode as a clinical-stage personalized cancer immunotherapy company targeting solid tumors with patient-specific approaches.
  • Gritstone bio: Gritstone bio develops personalized neoantigen cancer vaccines (GRANITE, SLATE programs) using viral vectors and self-amplifying RNA. Highly comparable to Nykode in clinical-stage personalized cancer immunotherapy targeting solid tumors.
  • Nouscom: Nouscom is a clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vector platforms. Closely comparable to Nykode's Vaccibody platform in terms of stage, modality (viral vector-based immunotherapies), and oncology focus.
  • Immatics: Immatics develops TCR-based immunotherapies and adoptive cell therapies targeting tumor-specific antigens, including ACTengine and TCER programs. Comparable to Nykode as a clinical-stage European immunotherapy company focused on cancer vaccines and cellular approaches.
  • Moderna: Moderna operates an mRNA therapeutics platform with active personalized cancer vaccine programs (e.g., mRNA-4157 with Merck). Comparable to Nykode as a platform-based therapeutic vaccine company targeting oncology, with similar partnership-driven business model.
  • CureVac: CureVac develops mRNA-based cancer vaccines and protein-based therapeutics. Comparable to Nykode as a clinical-stage European biotechnology company focused on therapeutic cancer vaccines with a platform-based approach.
  • BioNTech: BioNTech is a clinical-to-commercial mRNA-based immunotherapies company developing personalized cancer vaccines (e.g., BNT122/Autogene cevumeran) with Roche. Direct comparable to Nykode's Vaccibody platform in therapeutic cancer vaccines, especially in HPV-induced and personalized neoantigen indications.

Broad incumbents

  • Merck & Co. (MSD): Merck is a global pharmaceutical leader with Keytruda (pembrolizumab) as the dominant PD-1/PD-L1 immunotherapy, often used in combination with therapeutic cancer vaccines including Moderna's mRNA-4157. Comparable as a likely combination partner and acquirer of clinical-stage cancer vaccine assets like Nykode's pipeline.
  • Bristol-Myers Squibb: Bristol-Myers Squibb is a major immuno-oncology player with Opdivo (nivolumab) and Yervoy (ipilimumab). Comparable as a broad incumbent with overlapping combination immunotherapy interests relevant to Nykode's checkpoint inhibitor combination strategy.

Emerging players

  • Hookipa Pharma: Hookipa Pharma develops arenavirus-based immunotherapies for cancer and infectious diseases. Comparable to Nykode as a clinical-stage platform-based immunotherapy company, though using a distinct viral vector technology for antigen delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Customer concentration

Nykode social profiles

Digital presence

Nykode financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nykode leadership team

Management profile

Number of profiles

Profiles3 records

Nykode funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nykode M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nykode

What does Nykode do?

Nykode Therapeutics develops immunotherapies based on its proprietary Vaccibody platform, a modular molecule technology designed to induce fast, strong, and long-lasting immune responses. Its lead candidates include VB10.16, an off-the-shelf therapeutic cancer vaccine being co-developed with Roche for advanced cervical cancer, and abi-suva (VB-C-03), an experimental immunotherapy for HPV16-positive head and neck cancer currently in the Abili-T Phase II trial.

Is Nykode a public or private company?

Nykode is a public company. It is classified as public and is currently operating.

When was Nykode founded?

Nykode was founded in 2007. It employs 51 to 100 people.

Where is Nykode based?

Nykode is headquartered in Oslo, Norway, in the Europe region.

How does Nykode make money?

One revenue line is on record: partnership and Collaboration Revenue.

Who are Nykode's main competitors?

Direct peers on record are Achilles Therapeutics, Gritstone bio, Nouscom, Immatics, Moderna, CureVac and BioNTech. Broad incumbents are Merck & Co. (MSD) and Bristol-Myers Squibb. Hookipa Pharma is listed as an emerging player.

Does Nykode have an API?

No public API is recorded for Nykode.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingNykode Therapeutics Plans Phase 2 Abi-Suva Cancer Vaccine Trial Design Presentation at ESMO 2026Nykode Therapeutics will present a trial-in-progress poster on its Phase 2 Abili-T study at the ESMO Congress 2026. The presentation will highlight the trial design for Abi-Suva, its lead cancer vaccine.The future of tradingNykode Therapeutics Wins Canadian Approval for Phase 2 Abili-T TrialNykode Therapeutics received Canadian regulatory approval for its Phase 2 Abili-T trial of cancer vaccine abi-suva with pembrolizumab. The trial targets HPV16-positive, PD-L1-positive recurrent or metastatic head and neck cancer, with first interim data expected in 2027.Ticker ReportNykode Therapeutics AS (OTCMKTS:VACBF) Stock Short Interest Jumps 67.6%Short interest in Nykode Therapeutics AS rose 67.6% to 2,480 shares as of September 15th, up from 1,480 on August 31st. The stock opened at $0.45, with a 52-week range of $0.32 to $0.45. The company develops targeted immunotherapies for cancer and autoimmune diseases.Markets DailyNykode Therapeutics AS (OTCMKTS:VACBF) Stock Short Interest Climbs 67.6%Short interest in Nykode Therapeutics AS rose 67.6% to 2,480 shares as of September 15th, up from 1,480 on August 31st. The stock opened at $0.45, with a 4.1-day days-to-cover ratio based on 600 shares average volume.E24Oppgang på Oslo Børs – Nykode faller tungtOslo Børs main index rose about 0.5% on the first trading day, with oil prices up over 3%. Nykode Therapeutics lost a tax case, causing its stock to fall nearly 8%.StartupmafiaThe Best Startup Ecosystems in Norway: Bergen — the blue economy specialistBergen is Norway's most sector-specialized startup city, with clusters in seafood, media technology, and marine science. It has 26 funded companies raising $301M, but faces thin venture depth and a center-of-gravity drift. The article advises founders to target sector-specific clusters and raise externally.Investing.comEarnings call transcript: Nykode Therapeutics rises on q2 2026 vaccine progress By Investing.comNykode Therapeutics reported a Q2 2026 net loss of $7.2 million, down from a NOK 800,000 profit a year earlier, as higher clinical spending on its Abili-T head and neck cancer vaccine trial offset lower employee benefits. Cash of NOK 44.8 million supports operations into 2028, with a possible extension to 2029 if a pending NOK 33.4 million tax case is won. Abili-T, active in four countries, targets interim results in 2027.E24Nedgang på Oslo BørsOslo Børs opened lower on Wednesday, with the main index down 0.65 percent. Oil stocks fell after Brent spot dropped about 3 percent, and Soiltech dropped 6.74 percent after a block sale. MPC Container Ships and Nykode Therapeutics also reported results.MarketScreenerNykode Therapeutics Wins New US Patent for Neoantigen-based Cancer VaccineNykode Therapeutics has been granted a new US patent for its neoantigen-based cancer vaccine technology. The company is a Norway-based clinical-stage biopharmaceutical firm focused on developing vaccines and immunotherapies for cancer and infectious diseases. This development secures intellectual property rights for its therapeutic candidates in the United States market.Seeking AlphaNykode Therapeutics AS 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:VACBF) 2026-05-27Nykode Therapeutics AS published its Q1 2026 earnings results through a slide deck associated with an earnings call. No additional details about the results or strategic implications are provided in the article.